Literature DB >> 8628685

Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.

S Gryaznov1, T Skorski, C Cucco, M Nieborowska-Skorska, C Y Chiu, D Lloyd, J K Chen, M Koziolkiewicz, B Calabretta.   

Abstract

Uniformly modified oligonucleotide N3'-->P5' phosphoramidates, where every 3'-oxygen is replaced by a 3'-amino group, were synthesized. These compounds have very high affinity to single-stranded RNAs and thus have potential utility as antisense agents. As was shown in this study, the oligonucleotide phosphoramidates are resistant to digestion with snake venom phosphodiesterase, to nuclease activity in a HeLa cell nuclear extract, or to nuclease activity in 50% human plasma, where no significant hydrolysis was observed after 8 h. These compounds were used in various in vitro cellular systems as antisense compounds addressed to different targeted regions of c-myb, c-myc and bcr-abl mRNAs. C-myb antisense phosphoramidates at 5 microM caused sequence and dose-dependent inhibition of HL-60 cell proliferation and a 75% reduction in c-myb protein and RNA levels, as determined by Western blot and RT-PCR analysis. Analogous results were observed for anti-c-myc phosphoramidates, where a complete cytostatic effect for HL-60 cells was observed at 1 microM concentration for fully complementary, but not for mismatched compounds, which were indistinguishable from untreated controls. This was correlated with a 93% reduction in c-myc protein level. Moreover, colony formation by the primary CML cells was also inhibited 75-95% and up to 99% by anti-c-myc and anti-bcr-abl phosphoramidate oligonucleotides, respectively, in a sequence- and dose-dependent manner within a 0.5 nM-5 microM dose range. At these concentrations the colony-forming ability of normal bone marrow cells was not affected. The presented in vitro data indicate that oligonucleotide N3'-->P5' phosphoramidates could be used as specific and efficient antisense agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8628685      PMCID: PMC145826          DOI: 10.1093/nar/24.8.1508

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  34 in total

Review 1.  The interaction of intercalators and groove-binding agents with DNA triple-helical structures: the influence of ligand structure, DNA backbone modifications and sequence.

Authors:  W D Wilson; S Mizan; F A Tanious; S Yao; G Zon
Journal:  J Mol Recognit       Date:  1994-06       Impact factor: 2.137

Review 2.  Phosphorodithioate DNA as a potential therapeutic drug.

Authors:  W S Marshall; M H Caruthers
Journal:  Science       Date:  1993-03-12       Impact factor: 47.728

3.  Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

Authors:  T Skorski; M Nieborowska-Skorska; N C Nicolaides; C Szczylik; P Iversen; R V Iozzo; G Zon; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts.

Authors:  S T Crooke; L R Grillone; A Tendolkar; A Garrett; M J Fratkin; J Leeds; W H Barr
Journal:  Clin Pharmacol Ther       Date:  1994-12       Impact factor: 6.875

5.  Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.

Authors:  E Bayever; P L Iversen; M R Bishop; J G Sharp; H K Tewary; M A Arneson; S J Pirruccello; R W Ruddon; A Kessinger; G Zon
Journal:  Antisense Res Dev       Date:  1993

6.  Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.

Authors:  D A Brown; S H Kang; S M Gryaznov; L DeDionisio; O Heidenreich; S Sullivan; X Xu; M I Nerenberg
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

7.  Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.

Authors:  N M Dean; R McKay; T P Condon; C F Bennett
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

8.  Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration.

Authors:  S Biro; Y M Fu; Z X Yu; S E Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

9.  Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion.

Authors:  J R Wyatt; T A Vickers; J L Roberson; R W Buckheit; T Klimkait; E DeBaets; P W Davis; B Rayner; J L Imbach; D J Ecker
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

10.  p120 GAP requirement in normal and malignant human hematopoiesis.

Authors:  T Skorski; P Kanakaraj; M Nieborowska-Skorska; M Ratajczak; C Szczylik; G Zon; R B Arlinghaus; A Gewirtz; B Perussia; B Calabretta
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  20 in total

1.  Antisense delivery using protamine-oligonucleotide particles.

Authors:  M Junghans; J Kreuter; A Zimmer
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

2.  Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb.

Authors:  I J Moon; Y Lee; C S Kwak; J H Lee; K Choi; A D Schreiber; J G Park
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

3.  In vitro suicide inhibition of self-splicing of a group I intron from Pneumocystis carinii by an N3' --> P5' phosphoramidate hexanucleotide.

Authors:  S M Testa; S M Gryaznov; D H Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 4.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

5.  DNA polymerase activity on synthetic N3'→P5' phosphoramidate DNA templates.

Authors:  Victor S Lelyveld; Derek K O'Flaherty; Lijun Zhou; Enver Cagri Izgu; Jack W Szostak
Journal:  Nucleic Acids Res       Date:  2019-09-26       Impact factor: 16.971

6.  Selective inhibition of cell-free translation by oligonucleotides targeted to a mRNA hairpin structure.

Authors:  R Le Tinévez; R K Mishra; J J Toulmé
Journal:  Nucleic Acids Res       Date:  1998-05-15       Impact factor: 16.971

7.  RNase H-independent antisense activity of oligonucleotide N3 '--> P5 ' phosphoramidates.

Authors:  O Heidenreich; S Gryaznov; M Nerenberg
Journal:  Nucleic Acids Res       Date:  1997-02-15       Impact factor: 16.971

8.  alpha-Oligodeoxyribonucleotide N3'-->P5' phosphoramidates: synthesis and duplex formation.

Authors:  K Pongracz; S M Gryaznov
Journal:  Nucleic Acids Res       Date:  1998-02-15       Impact factor: 16.971

9.  Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo.

Authors:  T Skorski; D Perrotti; M Nieborowska-Skorska; S Gryaznov; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

10.  RNA mimetics: oligoribonucleotide N3'-->P5' phosphoramidates.

Authors:  S M Gryaznov; H Winter
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.